GlobeNewsWire
13 Jun 2026, 01:30 UTC · 14w ago
Verdict
Headline takes no side. We score BLTE +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Belite Bio has completed the rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant to treat Stargardt disease type 1 (STGD1).
More positive than 93% of claims this week
Tinlarebant has received Breakthrough Therapy Designation (BTD) from the FDA, which may expedite the regulatory review process.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 64% of claims this week
There are currently no approved treatment options for STGD1, which affects approximately 53,000 people in the U.S.
More positive than 64% of claims this week
The Phase 3 DRAGON trial demonstrated that tinlarebant significantly reduced the growth rate of retinal lesions compared to a placebo.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company completed its rolling NDA submission for tinlarebant, a potential first-in-class treatment for Stargardt disease type 1.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
+22.1%
Price agrees with the score
$168.67 vs $138.16 close before publication (Jun 12) · not market-adjusted
BLTE chart →
